
Shares of Orthocell Ltd OCC.AX rise 3.8% to A$1.52, their highest since April 10
The biotech firm receives regulatory approval from Health Canada to commence sales of its flagship nerve repair product Remplir in Canadian market
Co says first sales expected in the second half of 2025
Stock up 11.1% YTD, including moves in the current session